ASHMI stands for Anti-Asthma Herbal Medicine Intervention. ASHMI is a combination of three Chinese herbal extracts: Lingzhi Mushroom (aka Reishi Mushroom), Kushen (aka Sophora Root), and Licorice Root (aka Gancao).

Complementary and alternative medicines are increasingly used for the treatment of asthma in Western countries. A novel three-herb antiasthma herbal medicine intervention (ASHMI™; Sino-Lion Pharmaceutical Company; Shan Dong China) was demonstrated ...

2021年11月8日 · ASHMI, which stands for the Anti-Asthma Herbal Medicine Intervention, is a relatively simple herbal formula, containing just three Chinese herbs: Reishi (Ling Zhi), Sophora (Ku Shen), and Licorice (Gan Cao).

We developed a novel traditional Chinese medicine to treat asthma called antiasthma simplified herbal medicine intervention (ASHMI). Herbal products may offer safer adjunctive treatment …

We hypothesized that ASHMI ™ and some of its active compounds may suppress neutrophil predominant airway inflammation in vivo. Further we hypothesized that TNF-α, IL-8 and IL-17, critical to underlying mechanisms of neutrophilic inflammation, would be regulated by administration of ASHMI.

2008年1月15日 · 我们开发了一种由 3 种草药组成的中草药配方，称为 ASHMI。 先前在小鼠研究中表明，ASHMI（一种含有灵芝、苦参和甘草的配方）对哮喘-气道高反应性、肺部炎症和气道重塑的主要致病机制具有治疗作用，以及下调调节 TH2 反应。

Anti-asthma herbal medicine intervention (ASHMI™), a combination of three traditional Chinese medicinal herbs developed in our laboratory, has demonstrated efficacy in both mouse models of allergic asthma, and a double-blind placebo-controlled ...

开发了一种基于系统药理学的方法，结合了ADME评估，草药特征图绘制，药物靶向捕捞，网络药理学以及途径分析，以全面阐明哮喘的潜在治疗机制，例如抗哮喘草药干预（ASHMI） ）。

2019年1月1日 · The comprehensive analysis of ASHMI based on systems pharmacology not only opens up new ideas to disclose the scientific connotation of multiple systems of ASHMI, but also significantly improves our understanding of the complex molecular pathogenesis and therapeutic mechanism of asthma at the system level, so as to promote the drug discovery ...

2009年7月8日 · A novel three-herb antiasthma herbal medicine intervention (ASHMI™; Sino-Lion Pharmaceutical Company; Shan Dong China) was demonstrated to be effective and safe in a murine model of asthma and in a preliminary clinical study in China.